These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17937829)

  • 21. Special funding schemes for innovative medical devices in French hospitals: the pros and cons of two different approaches.
    Martelli N; van den Brink H
    Health Policy; 2014 Jul; 117(1):1-5. PubMed ID: 24794738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-introduction observation of healthcare technologies after coverage: the Spanish proposal.
    Varela-Lema L; Ruano-Ravina A; Mota TC; Ibargoyen-Roteta N; Imaz I; Gutiérrez-Ibarluzea I; Blasco-Amaro JA; Soto-Pedre E; Sampietro-Colom L
    Int J Technol Assess Health Care; 2012 Jul; 28(3):285-93. PubMed ID: 22980706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National Authority for Health: France.
    Rochaix L; Xerri B
    Issue Brief (Commonw Fund); 2009 Jul; 58():1-9. PubMed ID: 19639712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of coverage with evidence development for medical technologies in Switzerland from 1996 to 2012.
    Brügger U; Ruckstuhl A; Horisberger B; Gratwohl A
    Int J Technol Assess Health Care; 2014 Jul; 30(3):253-9. PubMed ID: 25100035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using evidence to inform coverage decisions: the Washington State experience.
    Blackmore CC
    Acad Radiol; 2012 Sep; 19(9):1055-9. PubMed ID: 22877985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New French Coverage with Evidence Development for Innovative Medical Devices: Improvements and Unresolved Issues.
    Martelli N; van den Brink H; Borget I
    Value Health; 2016 Jan; 19(1):17-9. PubMed ID: 26797231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Roadmap for Improving Medicare's Application of Coverage With Evidence Development.
    Lakdawalla D; Tunis S; Neumann P; Whicher D; Zeitler E; Liden B
    Value Health; 2024 May; ():. PubMed ID: 38795958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uncertainties in real-world decisions on medical technologies.
    Lu CY
    Int J Clin Pract; 2014 Aug; 68(8):936-40. PubMed ID: 25074335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reducing wasteful innovation.
    Siriwardena AN
    Qual Prim Care; 2013; 21(5):267-8. PubMed ID: 24119511
    [No Abstract]   [Full Text] [Related]  

  • 30. Joint project of the International Network of Agencies for Health Technology Assessment--Part 2: Managing the diffusion of positron emission tomography with health technology assessment.
    Adams EJ; Almazán C; Mørland B; Bradbury I; King R; Rheinberger P
    Int J Technol Assess Health Care; 2006; 22(2):149-54. PubMed ID: 16571189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Harmonization of evidence requirements for health technology assessment in reimbursement decision making.
    Hutton J; Trueman P; Facey K
    Int J Technol Assess Health Care; 2008; 24(4):511-7. PubMed ID: 18828948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.
    Stafinski T; McCabe CJ; Menon D
    Pharmacoeconomics; 2010; 28(2):113-42. PubMed ID: 20085389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Technology assessment and knowledge brokering: the case of assisted reproduction in The Netherlands.
    van Kammen J; Jansen CW; Bonsel GJ; Kremer JA; Evers JL; Wladimiroff JW
    Int J Technol Assess Health Care; 2006; 22(3):302-6. PubMed ID: 16984057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. When and how to assess fast-changing technologies: a comparative study of medical applications of four generic technologies.
    Mowatt G; Bower DJ; Brebner JA; Cairns JA; Grant AM; McKee L
    Health Technol Assess; 1997; 1(14):i-vi, 1-149. PubMed ID: 9483162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medicare's coverage of colorectal cancer drugs: a case study in evidence development and policy.
    Carino T; Williams RD; Colbert AM; Bridger P
    Health Aff (Millwood); 2006; 25(5):1231-9. PubMed ID: 16966718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health technology assessment.
    Kearney B
    J Qual Clin Pract; 1996 Sep; 16(3):131-43. PubMed ID: 8887856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology--part 2: coverage.
    Raab GG; Parr DH
    J Am Coll Radiol; 2006 Oct; 3(10):772-7. PubMed ID: 17412167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The nurse's role in contributing to new device development.
    Weir H; Grocott P; Ram MB
    Nurs Times; 2006 Jun 27-Jul 3; 102(26):36-9. PubMed ID: 16845815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality, innovation, and value for money: NICE and the British National Health Service.
    Pearson SD; Rawlins MD
    JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Technology assessment, coverage decisions, and conflict: the role of guidelines.
    Sheingold SH
    Am J Manag Care; 1998 Sep; 4 Spec No():SP117-25. PubMed ID: 10185988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.